NCT04439240View on ClinicalTrials.gov

Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

June 6, 2019

Study Completion Date

June 30, 2020

Conditions
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory Plasma Cell Myeloma
Interventions
DRUG

FGFR Inhibitor AZD4547

Given PO

Trial Locations (1)

19103

ECOG-ACRIN Cancer Research Group, Philadelphia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT04439240 - Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) | Biotech Hunter | Biotech Hunter